Cover [Abstract]
Statement [Table]
Statement [Table]
Class of Stock [Axis]
Class of Stock [Domain]
Common Stock
Common stock warrants
Statement [Line Items]
Statement [Line Items]
Document Type
Document Type
Document Quarterly Report
Document Period End Date
Document Period End Date
Document Transition Report
Entity File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Document Fiscal Year Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
CONDENSED CONSOLIDATED BALANCE SHEETS
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
Current assets:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Total prepaid expenses and other current assets
Assets, Current
Total current assets
Other Assets, Noncurrent
Other assets
Assets
Total assets
Liabilities and Equity [Abstract]
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Liabilities, Current [Abstract]
Current liabilities:
Accounts Payable, Current
Accounts payable
Accrued Liabilities, Current
Accrued and other current liabilities
Total accrued and other current liabilities
Accrued clinical site costs.
Accrued clinical site costs
Accrued clinical site costs
Convertible notes payable accrued interest.
Convertible Notes Payable Accrued Interest
Convertible note payable and accrued interest - short term
Carrying value as of the balance sheet date of insurance loans.
Insurance loan payable
D&O insurance payable
Derivative Liability, Current
Warrant liabilities
Liabilities, Current
Total current liabilities
Notes payable and accrued interest non current.
Notes payable and accrued interest non current
Convertible note payable and accrued interest - long term
Liabilities
Total liabilities
Preferred Stock, Value, Issued
Preferred stock, $0.001 par value, 50,000,000 shares authorized; Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 3,000,000 and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common Stock, Value, Issued
Common stock, $0.001 par value, 500,000,000 shares authorized; 83,919,554 and 66,442,989 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Additional Paid in Capital
Additional paid-in capital
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Stockholders' Equity Attributable to Parent
Ending balance
Beginning balance
Total stockholders' (deficit) equity
Liabilities and Equity
Total liabilities and stockholders' (deficit) equity
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Common Stock, Par or Stated Value Per Share
Common stock, par value
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Outstanding
Common stock, shares outstanding
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Operating Expenses [Abstract]
Operating expenses:
Research and Development Expense
Research and development expenses
General and Administrative Expense
General and administrative
Litigation Settlement, Expense
Settlement expense
Operating Expenses
Total operating expenses
Operating Income (Loss)
Loss from operations
Nonoperating Income (Expense) [Abstract]
Other (income) expenses:
Interest Income, Other
Interest income
Interest Expense
Interest expense
Interest repayments
The increase (decrease) in fair value of convertible debt during the period.
Increase (Decrease) In Fair Value Of Convertible Debt
Change in fair value of convertible note payable
Change in fair value of convertible promissory note
Fair value adjustment through earnings
Derivative, Gain (Loss) on Derivative, Net
Change in fair value of warrant liabilities
Change in fair value of warrant liability
Net Increase or Decrease in the fair value of the earn out liabilities included in earnings in the period.
Gain (Loss) on Fair Value of Cash Earnout Liability
Change in fair value of earnout cash liability
Nonoperating Income (Expense)
Total other (income) expenses
Net Income (Loss) Attributable to Parent
Net loss
Net loss
Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, Reclassification Adjustment from AOCI for Derecognition, after Tax
Change in fair value of convertible note attributed to credit risk
Change in fair value of convertible note attributed to credit risk
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive loss
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive loss
Earnings Per Share [Abstract]
Net loss per share:
Earnings Per Share, Basic
Basic
Earnings Per Share, Diluted
Diluted
Weighted average common shares outstanding:
Weighted Average Number of Shares Outstanding, Basic
Basic
Weighted Average Number of Shares Outstanding, Diluted
Diluted
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY
Equity Components [Axis]
Equity Component [Domain]
Preferred Stock [Member]
Preferred Stock
Additional Paid-in Capital
Accumulated Deficit
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income
Series A Preferred Stock
Shares, Outstanding
Ending balance ,shares
Beginning balance ,shares
Represents the value of common stock and warrants issued in a private placement, net of issuance costs.
Common Stock And Warrants Issued In Private Placement, Net Of Issuance Costs
Common stock and warrants issued, net of issuance costs
Represents the number of shares of common stock issued in a private placement of common stock and warrants.
Common Stock And Warrants Issued In Private Placement, Number Of Shares
Common stock and warrants issued, net of issuance costs (in shares)
Shares of common stock sold
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Stock-based compensation
Represents the value of stock issued for payment of consulting services.
Stock Issued For Payment Of Consulting Services
Common stock issued for consulting services
The number of shares of stock issued for payment of consulting services.
Shares Of Stock Issued For Payment Of Consulting Services
Common stock issued for consulting services (in shares)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Additional issuance costs in connection with Private Placement
Value of preferred stock and warrants issued during the period.
Preferred Stock and Warrants Issued During Period, Value
Preferred stock and warrants issued, net of issuance costs
Number of preferred stock and warrants issued during the period.
Preferred Stock and Warrants Issued During Period, Shares
Preferred stock and warrants issued, net of issuance costs (in shares)
Value of shares of stock issued attributable to settlement of liability.
Stock Issued During Period, Value, Settlement of Liability
Common stock issued to settle GEM settlement liability
Number of shares of stock issued attributable to settlement of liability.
Stock Issued During Period, Shares, Settlement of Liability
Common stock issued to settle GEM settlement liability (in shares)
Stock Issued During Period, Value, Conversion of Convertible Securities
Issuance of common stock as principal and interest repayment for convertible notes
Common stock issued as repayment of principal and interest for convertible note
Stock Issued During Period, Shares, Conversion of Convertible Securities
Common stock issued as repayment of principal and interest for convertible note (in shares)
Amount of increase in additional paid in capital (APIC) resulting from deferred offering cost settlement.
Adjustments to Additional Paid in Capital, Deferred Offering Cost Settlement
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Restricted stock awards granted (in Shares)
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
Restricted stock awards granted
Represents the issuance costs associated with a sale of stock and warrants.
Sale Of Stock And Warrants, Issuance Costs
Preferred, common stock and warrants issued, issuance costs
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Net Cash Provided by (Used in) Operating Activities [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Depreciation expense
Share-based Payment Arrangement, Noncash Expense
Stock-based compensation
Fair Value Adjustment of Warrants
Change in fair value of warrant liabilities
Noncash Settlement Expense.
Noncash Settlement Expense
Non-cash settlement expense
Increase (Decrease) in Operating Capital [Abstract]
Increases (decreases) in operating assets and liabilities:
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other assets
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued expenses and other liabilities
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
CASH FLOWS FROM INVESTING ACTIVITIES
Payments to Acquire Productive Assets
Purchase of computer equipment
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from (Repayments of) Notes Payable
Repayment of note payable
The cash outflow for a repayment of a convertible note.
Repayments of convertible note
Repayment of convertible note
The cash outflow for the payment of insurance loan.
Repayments of Insurance Loan
Repayment of insurance loan
The cash inflow from issuance of insurance loan
Proceeds from issuance of insurance loan
Proceeds from issuance of insurance loan
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants
Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs
Represents net proceeds (payments) for issuance of common stock and warrants in a private placement, net of issuance costs.
Net Proceeds From (Payments For) Issuance Of Common Stock And Warrants In Private Placement, Net Of Issuance Costs
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Net (decrease) increase in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents at end of period
Cash and cash equivalents at beginning of period
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Non-cash investing and financing activities
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Issuance of Common Stock Warrants as Offering Costs
Issuance of Common Stock Warrants as Offering Costs
Issuance of common stock warrants as offering costs
Stock Issued
Issuance of common stock for settlement of accrued liability
Organization
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Organization
Liquidity [Abstract]
Liquidity
Liquidity [Text Block]
Liquidity [Text Block]
Liquidity
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Prepaid Expenses and Other Current Assets
The entire disclosure of prepaid expenses and other current assets.
Disclosure of Prepaid Expenses and Other Current Assets [Text Block]
Prepaid Expenses and Other Current Assets
Accrued and Other Current Liabilities
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Accrued and Other Current Liabilities
No definition available.
Alvogen Licensing Agreement
The disclosure of Alvogen licensing agreement.
Alvogen Licensing Agreement [Text Block]
Alvogen Licensing Agreement
Debt.
Debt Disclosure [Text Block]
Debt
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Equity
Stockholders' Equity Note Disclosure [Text Block]
Equity
Stock-Based Compensation
Share-based Payment Arrangement [Text Block]
Stock-Based Compensation
Fair Value Measurements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]
Fair Value Measurements
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Risk And Uncertainties Policy [Text Block]
Risk And Uncertainties Policy [Text Block]
Certain Risks and Uncertainties
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk and Off-Balance Sheet Risk
Revenue [Policy Text Block]
Revenue Recognition
Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs
Debt, Policy [Policy Text Block]
Convertible Note Payable
Share-based Payment Arrangement [Policy Text Block]
Stock-Based Compensation
information expressed about Warrant policies
Warrant Liability [Policy Text Block]
Warrants
information expressed about Modification of Warrants.
Modification Of Warrants [Policy Text Block]
Modification of warrants
Disclosure of accounting policy for preferred stock.
Preferred Stock Policy [Policy Text Block]
Preferred Stock
Income Tax, Policy [Policy Text Block]
Income Taxes
Earnings Per Share, Policy [Policy Text Block]
Loss Per Share
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Outstanding Shares of Common Stock Equivalents Excluded From Diluted Net Loss Per Share
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Schedule of prepaid expenses and other current assets
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Schedule of accrued and other current liabilities
Convertible Debt [Table Text Block]
Summary of Convertible note payable
Schedule of Stock by Class [Table]
Class of Stock [Line Items]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Summary of activity for warrants
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Summary of fair value determined using the Black-Scholes option-pricing model
Share-based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of stock option activity
Share-based Payment Arrangement, Cost by Plan [Table Text Block]
Summary of recognition of stock-based compensation
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
Schedule of restricted stock activity
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Liability Class [Axis]
Fair Value by Liability Class [Domain]
Convertible Notes Payable [Member]
Convertible notes payable
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Summary of fair value hierarchy
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of measure the convertible note liability
No definition available.
Schedule Of Warrant Liability Valuation Assumptions Table Text Block
Schedule of significant unobservable inputs
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of reconciliation of liabilities
Schedule of Related Party Transactions, by Related Party [Table]
Product and Service [Axis]
Product and Service [Axis]
Product and Service [Domain]
Product and Service [Domain]
Represents the information pertaining to therapeutic product, NRX-101.
Therapeutic Product, NRX-101 [Member]
NRX-101
Represents the information pertaining to therapeutic product, NRX-100.
NRX-100
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Represents the information pertaining to Exclusive, Global - Development, Supply, Marketing & License Agreement.
Exclusive, Global - Development, Supply, Marketing & License Agreement [Member]
License Agreement
Counterparty Name [Axis]
Counterparty Name [Axis]
Counterparty Name [Domain]
Counterparty Name [Domain]
Represents the information pertaining to Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.
Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd [Member]
Alvogen
Related Party Transaction [Line Items]
It represents the number of participants reviewed.
Number Of Participants Reviewed
Number Of Participants Reviewed
The percentage of standard set for veteran rating team and site raters.
Percentage Of Standard Set For Veteran Rating Team And Site Raters
Percentage of standard set for veteran rating team and site raters
Percentage of threshold congruence achieved with Montgomery Asberg Depression Rating Scale (MADRS), which constitutes the primary efficacy endpoint.
Percentage Of Threshold Congruence Achieved
Percentage of threshold congruence achieved
Threshold number of states covered under the recruitment campaign.
Threshold Number Of States Covered Under The Recruitment Campaign
Threshold number of states covered under the recruitment campaign
Minimum shelf life of supplies.
Minimum Shelf Life Of Supplies
Minimum shelf life of supplies
Term of license agreement from the first commercial sale of Product.
License Agreement, Initial Term
Initial term
Renewal term of license agreement upon request made prior to the expiration of such initial term.
License Agreement, Renewal Term
Renewal term
Number of patients in inpatient trial.
Number Of Patients In Inpatient Trial
Number of patients in inpatient trial
Threshold number of patients' data that would be enough demonstrate preliminary safety and efficacy, as determined by the company.
Threshold Number Of Patients Data Enough To Demonstrate Preliminary Safety And Efficacy
Threshold number of patients' data that would be enough demonstrate preliminary safety and efficacy
Number of patients in randomized prospective trial.
Number Of Patients In Randomized Prospective Trial
Number of patients in randomized prospective trial
Schedule of Long-term Debt Instruments [Table]
Sale of Stock [Axis]
Sale of Stock [Domain]
Securities Purchase Agreement March 8, 2023.
Securities Purchase Agreement March 8, 2023 [Member]
Securities Purchase Agreement
Securities Purchase Agreement on June 6, 2023 aka "June Investors."
Securities Purchase Agreement June Investors
Represents information relating to securities purchase agreement August investors.
Securities purchase agreement, august investors
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Minimum
Minimum
Maximum
Maximum
Debt Instrument [Line Items]
Cash
Cash
Represents the price per unit.
Unit Price
Price per unit
Class of Warrant or Right, Exercise Price of Warrants or Rights
Outstanding at the end (in dollars per share)
Outstanding at the beginning (in dollars per share)
Warrants, exercise price per share
Warrants exercisable beginning term.
Warrants And Rights Exercisable Term
Warrants and rights exercisable term
Warrants and Rights Outstanding, Term
Warrants expiration term
Proceeds from Issuance of Common Stock
Proceeds from issuance of Common stock, net of transaction costs
Debt Instrument, Term
Maturity term
Stock Issued During Period, Shares, New Issues
Number of shares issued
Common stock issued (in shares)
Number of warrants issued with each share during the period.
Number Of Warrants Issued With Each Share
Number of warrants issued with each share
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Number of shares per warrant
Share Price
Stock price on valuation date
Closing price
Represents threshold common stock price on the specified trading days for warrants to be exercisable.
Warrants Exercisable, Common Stock Price Threshold , Specified Trading Days
Warrants exercisable, common stock price threshold , specified trading days
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Share-based Payment Arrangement, Option [Member]
Stock options
Restricted stock awards
Convertible preferred stock
Information related to Public Rights pursuant to UPOs
Earnout Shares
Information pertaining to earnout shares from exercised Substitute Options and Substitute Warrants.
Earnout Shares from exercised Substitute Options and Substitute Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Amount of clinical development expenses paid in advance.
Prepaid Clinical Development Expenses
Prepaid clinical development expenses
Prepaid Insurance
Prepaid insurance
Other Prepaid Expense, Current
Other prepaid expenses
Prepaid legal expenses.
Prepaid Legal Expenses
Prepaid legal expenses
Accounts and Other Receivables, Net, Current
Other current receivables
Accrued Liabilities and Other Liabilities [Abstract]
Accrued and other current liabilities:
Amount of other expenses incurred but not yet paid , due within one year or the normal operating cycle, if longer.
Other Accrued Expenses, Current
Other accrued expenses
Accrued Employee Benefits, Current
Accrued employee expenses
Accrued Research And Development Expenses Current
Accrued Research And Development Expenses Current
Accrued research and development expenses
Accrued Professional Fees, Current
Professional services
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Alvogen Licensing Agreement
Number of business days for payment of equitable royalty in case of reversion license.
License Agreement, Minimum Period for Equitable Royalty Payable In Case of Reversion License
Equity royalty payable period in case of reversion license
Initial cash payment to be received.
Initial Cash Payment to be Received
First milestone payment to be received
Second milestone payments receivable.
Second Milestone Payments Receivable
Second milestone payment receivable
Maximum bonus milestone payments receivable.
Maximum Bonus Milestone Payments Receivable
Maximum bonus milestone payment receivable
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Information pertaining to the 9% Redeemable Promissory Note.
Promissory Note 9% Redeemable [Member]
Scenario [Axis]
Scenario [Domain]
Represents the second amendment the company entered into on July 7 regarding the 9% note.
Amendment Two [Member]
Represents trigger events that indicate the 9% note is in default.
Default Trigger Events [Member]
Debt Instrument, Interest Rate, Stated Percentage
Interest rate percentage
Debt Instrument, Face Amount
Amount of original issue discount of debt instrument.
Debt Instrument, Original Issue Discount
Original issue discount
Proceeds from Notes Payable
Net proceeds from issuance of notes
Amount payable on prepayment of debt represented as a percentage of the principal, interest and fees owed as of the prepayment date.
Debt Instrument, Prepayment, Amount Payable As A Percentage Of Principal, Interest And Fees Owed
Amount payable on prepayment of notes as a percentage of the principal, interest, and fees owed
Maximum outstanding balance of the debt instrument that can be redeemed by the holder per month.
Debt Instrument, Maximum Outstanding Balance That Can Be Redeemed By The Holder Per Month
Maximum outstanding balance of the Note that can be redeemed by the holder per month
Percentage of premium payable on amount redeemed if the debt instrument is redeemed in cash.
Debt Instrument, Redemption, Percentage Of Premium Payable On Amount Redeemed If Redeemed In Cash
Percentage of premium payable on amount redeemed if the notes are redeemed in cash
Redemption Conversion Price of the debt instrument, as a percentage of average lowest daily volume weighted average prices per share of the company.
Debt Instrument, Redemption Conversion Price As A Percentage Of Average Lowest Daily Volume Weighted Average Prices Per Share
Redemption Conversion Price as a percentage of average lowest daily volume weighted average prices per share of the common stock
Number of lowest daily volume weighted average prices per share of the company considered for determination of Redemption Conversion Price of the debt instrument.
Debt Instrument, Redemption Conversion Price, Number Of Lowest Daily Volume Weighted Average Prices Per Share Considered
Redemption Conversion Price, Number of lowest daily volume weighted average prices per share of the common stock considered
Number of trading days over which the average of the lowest daily volume weighted average prices per share of the company is considered for determination of Redemption Conversion Price of the debt instrument.
Debt Instrument, Redemption Conversion Price, Number Of Trading Days Considered
Redemption Conversion Price, Number of trading days considered
Minimum percentage of daily dollar trading volume of the common stock considered to trigger redemption of debt instrument.
Debt Instrument, Redemption Trigger, Minimum Percentage Of Daily Dollar Trading Volume Of Common Stock Considered
Minimum percentage of daily dollar trading volume of the common stock considered to trigger redemption of Notes
Number of previous trading days over which the median daily dollar trading volume is considered to trigger redemption of Notes
Debt Instrument, Redemption Trigger, Number Of Previous Trading Days Over Which The Median Daily Dollar Trading Volume Is Considered
Number of previous trading days over which the median daily dollar trading volume is considered to trigger redemption of Notes
Minimum percentage by which the closing trade price exceeds the Nasdaq Minimum Price, considered to trigger the redemption of debt instrument.
Debt Instrument, Redemption Trigger, Minimum Percentage By Which The Closing Trade Price Exceeds The Nasdaq Minimum Price, Considered
Minimum percentage by which the closing trade price exceeds the Nasdaq Minimum Price, considered to trigger redemption of Notes
Number of following trading days over which the closing trade price is consider to trigger redemption of debt instrument.
Debt Instrument, Redemption Trigger, Number Of Following Trading Days Over Which The Closing Trade Price Is Considered
Number of following trading days over which the closing trade price is considered to trigger redemption of Notes
Monthly redemption amount of the debt instrument.
Debt Instrument, Monthly Redemption Amount
Monthly redemption amount
Represents information pertaining to maximum percentage of number of shares of Common Stock outstanding.
Maximum Percentage Of Common Stock Outstanding
Maximum percentage of Common Stock outstanding
Represents the amount agreed to pay in cash to amend the redemption provisions.
Debt Instrument, Amount Agreed To Pay In Cash To Amend The Redemption Provisions
Amount agreed to pay in cash to amend the redemption provisions
Represents the maximum monthly redemption amount per month.
Debt Instrument, Maximum Monthly Redemption Amount per Month
Maximum monthly redemption amount per month
Amount of the required periodic payments applied to interest paid in cash.
Debt Instrument, Periodic Payment, Interest Paid in Cash
Cash interest repayments made
Amount of the required periodic payments applied to interest paid in stock.
Debt Instrument, Periodic Payment, Interest Paid From Issuance of Stock
Shares of common stock issued as interest repayment
Amount of the required periodic payments applied to principal paid in cash.
Debt Instrument, Periodic Payment, Principal Paid in Cash
Cash principal repayments made
Amount of the required periodic payments applied to principal paid in stock.
Debt Instrument, Periodic Payment, Principal Paid From Issuance of Stock
Shares of common stock issued as principal repayment
Amount of minimum payment per month on or before the last day of each month in relation to debt instrument.
Debt Instrument, Minimum Monthly Payments
Minimum Payment
Debt Instrument, Convertible, Threshold Trading Days
Number of trading days
Debt Instrument, Unamortized Discount
Debt discount
Debt discount
Represents the number events causing 9% note to be in default..
Event of Default
Schedule of Short-term Debt [Table]
Short-term Debt [Line Items]
Long-term Debt, Gross
Par value of the Note
The amount of principal repaid under debt instrument.
Debt Instrument, Repayments of Principal
Repayment of Principal
Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt before adjustment to fair value of debt
Long-Term Debt before Fair Value Adjustments
Carrying value of the Note before current period change in fair value
The increase (decrease) in fair value of accumulated other comprehensive income from convertible debt during the period.
Increase (Decrease) In Fair Value accumulated other comprehensive income
Fair value adjustment through accumulated other comprehensive income
Long-term Debt
Total carrying value of Note
Long-term Debt, Current Maturities
Convertible note payable - current portion
Long-term Debt, Excluding Current Maturities
Convertible note payable, net of current portion
Commitments and Contingencies [Table]
Commitments and Contingencies [Table]
Commitments and Contingencies [Table]
This member represents the information relating to exclusive license agreement.
Exclusive License Agreement [Member]
Exclusive License Agreement
Commitments and Contingencies [Line Items]
Commitments and Contingencies [Line Items]
Commitments and Contingencies [Line Items]
Operating Lease, Expense
Share subscription agreement term.
Share Subscription Agreement Term
Share subscription agreement term
Commitment Fee Paid By Company
Commitment Fee Paid By Company
Commitment fee
Related Party Transaction, Amounts of Transaction
Payment to related party
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Sponsored research agreement.
Sponsored Research Agreement [Member]
Research and development commitments.
Research And Development Commitments
Research commitments
Relief Therapeutics Collaboration Agreement.
Relief Therapeutics Collaboration Agreement [Member]
Relief Therapeutics Collaboration Agreement
Litigation Status [Axis]
Litigation Status [Domain]
Relief Therapeutics Lawsuit [Member]
Represents information pertaining to Relief Therapeutics lawsuit.
Relief Therapeutics Lawsuit
Represents information pertaining to Relief Therapeutics Holdings, AG.
Relief Therapeutics Holdings, AG
The amount of milestone payments receivable under collaborative arrangement.
Collaborative Arrangement, Milestone Payments Receivable
Milestone payments receivable
The amount of royalty payments receivable under collaborative arrangement.
Collaborative Arrangement, Royalty Payments Receivable
Royalty payments receivable
The threshold amount of indemnity claims exceeding which, the company is not liable to pay
Collaborative Arrangement, Threshold Liability for Indemnity Claims
Indemnity claims
he threshold amount of indemnity obligations on breach of representations and warranties, exceeding which, the company is not liable to pay.
Collaborative Arrangement, Threshold Indemnity Obligation for Breach of Representations and Warranties
Representations and Warranties
The threshold amount of indemnity obligations on breach of covenants and other agreements, exceeding which, the company is not liable to pay.
Collaborative Arrangement, Threshold Indemnity Obligation for Breach of Covenants and Other Agreements
Covenants and Other Agreements
GEM Share Subscription Facility Agreement.
GEM Share Subscription Facility Agreement
Represents information pertaining to H.C. Wainwright & Co. LLC.
H.C. Wainwright & Co. LLC
Shares Issued, Price Per Share
The cash outflow on payments of fee under letter agreement.
Letter Agreement, Payments Of Cash Fee credit
Letter agreement, payments of cash fee credit
Percentage of cash fee paid under the letter agreement.
Letter Agreement, Percentage Of Cash Fee Paid
Percentage of cash fee paid under the letter agreement
The percentage of cash fee on gross proceeds received, paid to the placement agent under the securities purchase agreement.
Securities Purchase Agreement, Placement Agent Fee Percentage
Securities purchase agreement, placement agent fee percentage
Payments of Stock Issuance Costs
Less: transaction costs and advisory fees allocated to NRXP equity
Proceeds from Issuance or Sale of Equity
Proceeds from offering
Aggregate purchase price per unit of stock issued by the company.
Aggregate Cash Purchase Price Per Unit
Aggregate cash purchase price per unit
Price of the entity's common stock which would be required to be attained for the conversion of company's convertible preferred stock.
Preferred Stock, Convertible, Stock Price Trigger
Preferred stock conversion, stock price trigger
Period following the issuance date, upto which the shares of convertible preferred stock shall not be converted by the shareholder.
Preferred Stock, Convertible, Period During Which Shares Shall Not Be Converted
Preferred stock conversion, period during which shares shall not be converted
Threshold maximum percentage of outstanding common stock shares that shall be held by the shareholders after conversion of convertible preferred stock.
Preferred Stock Conversion, Threshold Maximum Percentage Of Outstanding Common Stock Shares To Be Held After Conversion
Preferred stock conversion, threshold maximum percentage of outstanding common stock shares
Convertible Preferred Stock, Shares Issued upon Conversion
Shares issued upon conversion
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Represents the information pertaining to Substitute Warrants.
Substitute Warrants
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Represents the information pertaining to merger agreement with merger sub and NeuroRx.
Merger agreement
Represents the information pertaining to stockholders of NeuroRx.
Stockholders of NeuroRx
Stockholders' Equity Note, Stock Split, Conversion Ratio
Exchange Ratio
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Exercise price
Strike price
Represents the information pertaining to Public Warrants.
Public Warrants
Class of Warrant or Right, Outstanding
Outstanding at the end
Outstanding at the beginning
Number of outstanding warrants
Represents the class of warrant or right exercised during the period.
Warrants Exercised During Period
Exercised
Warrants exercised during period
Represents the information pertaining to Placement Warrants.
Placement Warrants
Class of Warrant or Right [Table]
Represents the information pertaining to June Placement Agent Warrants.
June Placement Agent Warrants
Represents the information pertaining to Amended Warrants.
Amended Warrants
Represents the information pertaining to June Investor Amended Warrants.
June Investor Amended Warrants [Member]
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Stock price on valuation date
Exercise price per share
Expected life
Volatility
Risk-free rate
Dividend yield
Measurement input using fair value of share.
Fair value of warrants
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Expected term
Expected term (years)
Class of Warrant or Right, Fair Value
Class of Warrant or Right, Fair Value
Fair value on the date of issuance
Fair value portion of warrants.
Warrants Fair Value Disclosure
Warrants fair value disclosure
Aggregate number of warrants issued during the period.
Aggregate Number Of Warrants Issued
Aggregate number of warrants issued
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input
Warrants and rights outstanding, measurement input
No definition available.
Class of Warrant or Right, Number [Abstract]
Total Warrants
Class of warrant or right issued.
Class of Warrant or Right, Issued
Issued
No definition available.
Class of Warrant or Right, Weighted Average Remaining Term [Abstract]
Weighted Average Remaining Term
Represents the weighted average remaining contractual term of warrants.
Class Of Warrant Or Right Weighted Average Remaining Contractual Term 2
Outstanding
Represents the weighted average remaining contractual term of warrants issued.
Class of Warrant or Rights, Grant In Period Weighted Average Remaining Contractual Term
Issued (in years)
No definition available.
Class of Warrant or Right, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price
Represents the weighted average exercise price of warrants issued.
Class of Warrant or Right Exercise Price of Warrants or Rights Issued
Issued (in dollars per share)
Plan Name [Axis]
Plan Name [Domain]
Two Thousand Sixteen Omnibus Plan [Member]
Two Thousand Sixteen Omnibus Plan [Member]
2016 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Number of shares authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Outstanding at the end (in shares)
Outstanding at the beginning (in shares)
Options to purchase shares of common Stock
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding at the end (in dollars per share)
Outstanding at the beginning (in dollars per share)
Exercise price
Represents information pertaining to 2021 Omnibus Incentive Plan.
2021 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Number of additional shares authorized
Percentage of outstanding shares used to determine the number of additional shares authorized annually under the plan.
Option Awards Percentage Of Outstanding Shares Used To Determine Additional Shares Authorized Voting Interests Retained By Shareholders
Percentage of outstanding shares for determination of annual additional shares authorization
Represents the aggregate number of options granted to-date.
Share-Based Compensation Arrangement, Payment Award Options, Aggregate Granted
Number of shares awarded
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Number of shares available for issuance
Award Type [Axis]
Award Type [Domain]
Stock Options [Member]
Stock Options
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit
Exercise price minimum
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
Exercise price maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free rate of interest, minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free rate of interest, maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected stock price volatility
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Options vested and exercisable (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Options vested and exercisable (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining remaining term (in years)
Weighted average remaining contractual term for option awards outstanding during the period.
Share Based Compensation Arrangement Options Outstanding, Weighted Average Remaining Contractual Term 2
Outstanding (in years)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term
Options vested and exercisable (in years)
Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]
Aggregate intrinsic value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Outstanding at the end (in dollars)
Outstanding at the beginning (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Options vested and exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant date fair value
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Unrecognized compensation
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Weighted-average period
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Income Statement Location [Axis]
Income Statement Location [Domain]
General and administrative
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense
Stock-based compensation expense
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Balance, beginning of period
Balance, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Shares granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Shares vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Grant date fair value, beginning of period
End of period
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Unrecognized compensation, restricted stock
Measurement Frequency [Axis]
Measurement Frequency [Domain]
Fair Value, Recurring [Member]
Recurring basis
Level 1
Assets, Fair Value Disclosure [Abstract]
Assets:
Cash and Cash Equivalents, Fair Value Disclosure
Money Market Account
Liabilities, Fair Value Disclosure [Abstract]
Liabilities:
Convertible Debt, Fair Value Disclosures
Convertible note payable (Note 7)
Total carrying value of Note
Time to expiration
Measurement input using market interest rate.
Note market interest rate
Measurement input using equity volatility.
Equity volatility
Measurement input using volume volatility.
Volume volatility
Probability of default
Debt Instrument, Periodic Payment, Principal
Repayment of Principal
Convertible Debt
Carrying value of the Note before current period change in fair value
Convertible Debt, Current
Convertible note payable - current portion
Convertible Debt, Noncurrent
Convertible note payable, net of current portion
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Balance at the end
Balance at the beginning
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Gain upon re-measurement
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]
Income Tax Expense (Benefit)
Provision or benefit for income tax expense
Agreement [Axis]
Agreement [Axis]
Agreement [Domain]
Agreement [Domain]
Glytech Agreement [Member]
Glytech Agreement [Member]
Information pertaining to the PillTracker SOW.
PillTracker SOW
Related Party [Axis]
Related Party [Domain]
Information related to the former CEO.
Former Chief Executive Officer [Member]
Former CEO
Chief Executive Officer Son [Member]
Chief Executive Officer Son [Member]
Related Party [Member]
The minimum value of equity required for the transfer of assets from related parties to the Company.
Minimum Equity Value Required For Transfer Of Assets
Minimum equity required for transfer of Excluded Technology
Number of consecutive trading days required of minimum equity met for the transfer of assets from a related party to the Company.
Minimum Equity Required For Transfer Of Assets From Related Party, Number of Consecutive Trading Days
Number of consecutive trading days
Number of trading days required of minimum equity met for the transfer of assets from a related party to the Company.
Minimum Equity Required For Transfer Of Assets From Related Party, Number of Trading Days
Number of trading days
Threshold aggregate liquidity of the related party.
License Agreement, Threshold Aggregate Liquidity
Threshold aggregate liquidity of the related party
The amount of consulting fee payable per month under related party transactions.
Related Party Transaction, Consulting Fee Payable Per Month
Consulting fee payable per month
The amount of performance-based annual bonus with a minimum target payable under related party transaction.
Related Party Transactions, Performance Based Annual Bonus Minimum Target
Performance based annual bonus minimum target
Number of shares shall have restrictions removed on new drug application date.
Number of Shares, Restrictions Removed on New Drug Application Date
Number of shares, restrictions removed on new drug application date
Number of shares will have restrictions removed on new drug approval date.
Number of Shares, Restrictions Removed on New Drug Approval Date
Number of shares, restrictions removed on new drug approval date
Accounts Payable
Accounts payable due to related parties